Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer

Phase 2

Completed

Conditions: Penile Cancer

Interventions: Drug: Albumin-Bound Paclitaxel
Drug: Ifosfamide
Drug: Cisplatin
Drug: Nimotuzumab
Drug: Triprilimab

First Posted Date: 2020-07-17

Last Posted Date: 2022-06-09

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 29

Registration Number: NCT04475016

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients

Phase 1

Completed

Conditions: Oral Cancer
Induction Chemotherapy
Programmed Cell Death 1 Inhibitor
Inductive Therapy

Interventions: Drug: Toripalimab
Drug: Paclitaxcel
Drug: Cisplatin
Procedure: Radical surgery
Radiation: Post-operative radiotherapy/chemoradiotherapy

First Posted Date: 2020-07-16

Last Posted Date: 2023-11-22

Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 20

Registration Number: NCT04473716

Locations: 🇨🇳
Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

Efficacy and Safety of CRT, Durvalumab and Surgery for SST

Phase 3

Not yet recruiting

Conditions: Non Small Cell Lung Cancer Stage III
Superior Sulcus Tumor
Non-small Cell Lung Cancer Stage IIB

Interventions: Drug: Cisplatin
Drug: S1
Radiation: concurrent radiotherapy
Drug: Durvalumab
Procedure: Surgery

First Posted Date: 2020-07-10

Last Posted Date: 2020-07-10

Lead Sponsor: National Cancer Center Hospital East

Target Recruit Count: 84

Registration Number: NCT04465968

A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.

Phase 1

Conditions: Esophageal Cancer

Interventions: Drug: anti-PD-L1 antibody
Drug: albumin bound paclitaxel
Drug: placebo
Drug: cisplatin
Procedure: radical resection of esophageal carcinoma

First Posted Date: 2020-07-07

Last Posted Date: 2022-05-04

Lead Sponsor: Lee's Pharmaceutical Limited

Target Recruit Count: 70

Registration Number: NCT04460066

Locations: 🇨🇳
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Phase 3

Terminated

Conditions: Stage IVB Nasopharyngeal Carcinoma AJCC v8
Metastatic Nasopharyngeal Undifferentiated Carcinoma
Nasopharyngeal Nonkeratinizing Carcinoma
Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma
Recurrent Nasopharyngeal Undifferentiated Carcinoma
Metastatic Nasopharyngeal Carcinoma
Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma
Stage IV Nasopharyngeal Carcinoma AJCC v8
Stage IVA Nasopharyngeal Carcinoma AJCC v8
Metastatic Nasopharyngeal Nonkeratinizing Carcinoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Gemcitabine
Biological: Nivolumab
Other: Questionnaire Administration

First Posted Date: 2020-07-07

Last Posted Date: 2024-12-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT04458909

Locations: 🇺🇸
Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States
🇺🇸
Carle Cancer Center, Urbana, Illinois, United States
🇺🇸
Contra Costa Regional Medical Center, Martinez, California, United States

and more 322 locations

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

Phase 3

Terminated

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Xevinapant (Debio 1143)
Drug: Cisplatin
Radiation: Intensity Modulation Radiation Therapy (IMRT)
Drug: Placebo

First Posted Date: 2020-07-07

Last Posted Date: 2024-10-01

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 730

Registration Number: NCT04459715

Locations: 🇺🇸
Inventa Center for Cancer Research At Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇦
Medical center of Yuriy Spizhenko, Soborna Vulytsia, Kyiv, Ukraine

and more 282 locations

Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer

Phase 2

Active, not recruiting

Conditions: Colorectal Adenocarcinoma

Interventions: Drug: Temozolomide (TMZ)
Drug: Cisplatin
Drug: Nivolumab

First Posted Date: 2020-07-07

Last Posted Date: 2024-03-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 18

Registration Number: NCT04457284

Locations: 🇺🇸
Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States

and more 4 locations